Small molecule · Cytotoxic, directed at DNA (N3-adenine) · developed by Lantern Pharma
Zirdafulven (LP-184) is a tumor-site activated acylfulvene-derived prodrug that is converted by prostaglandin reductase 1 (PTGR1), an enzyme elevated in certain tumors. The active form alkylates DNA at N3-adenine, causing double-strand breaks that tumor cells with DNA damage repair deficiencies cannot repair. It is studied in solid tumors, triple-negative breast cancer, glioblastoma, non-small cell lung cancer, pancreatic adenocarcinoma and relapsed or refractory lymphomas.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05933265 | Phase 1/2 | Advanced Solid Tumor | Active not recruiting | LTRN |
| NCT06132503 | Phase 1 | Relapsed or Refractory Lymphomas | Recruiting | LTRN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorDDR Gene MutationGBMMetastatic Solid TumorNSCLCPancreatic AdenocarcinomaRelapsed or Refractory LymphomasTNBC - Triple-Negative Breast Cancer
Updated Oct 18, 2026. Something wrong or missing? Report it on the LTRN page.
See LTRN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LTRN catalysts and pipeline →